§ 1 Reasoning
The order was procedural — the merits of the FDA's mifepristone REMS modifications were not decided. The case continues in the Fifth Circuit with three state intervenors (originally Missouri, Idaho, Kansas; later transferred).
§ 2 Opinions
Majority
Not joined by any other justice
The Supreme Court granted an emergency stay, preserving the status quo for mifepristone access via telehealth and pharmacy while litigation continues in the Fifth Circuit.
§ 3 Practical effect
Mail-order and pharmacy-dispensed mifepristone remain available nationwide pending litigation. The Trump administration has not sought to revoke FDA approval, though FDA Commissioner Marty Makary launched a 'safety review' in May 2025.
§ 4 Perspectives
The summaries below are descriptive, not evaluative — an attempt to represent fairly how each camp typically frames this case.
Abolitionist framing
Abolitionists generally view the continued availability of mail-order abortion pills as the primary post-Dobbs loophole undermining state bans. Foundation to Abolish Abortion and similar groups argue the Comstock Act (18 U.S.C. §§ 1461–1462) already makes such mailings illegal and criticize the Trump administration for non-enforcement.
Mainstream pro-life framing
Groups like AUL and SBA Pro-Life America press for FDA reversal or Comstock enforcement, arguing chemical abortion has become the new frontier requiring federal action.
Pro-choice framing
Reproductive rights advocates hail the stay as preserving essential medication abortion access and criticize the underlying litigation as an attempt to impose a de facto national ban.
§ 5 Significance
7/ 10
The order itself is procedural, but the underlying dispute over mifepristone access is the most consequential unresolved federal abortion question post-Dobbs. Nearly two-thirds of U.S. abortions are now medication abortions.